Early Phase 1 Brain Cancer Trial, Recruiting NCT06613841 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Brain Cancer
Back to Brain Cancer

Early Phase 1 Brain Cancer Trial, Recruiting

NCT06613841
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have a newly found brain mass (a growth inside the brain tissue) that a specialist radiologist at Penn believes is consistent with glioblastoma (an aggressive type of brain tumour)
  • People who have a confirmed past diagnosis of glioblastoma (proven by tissue or molecular testing) and whose brain scans now show a new or significantly increased area of activity (more than 25% increase), which may suggest the tumour has returned or grown
  • People whose doctors have recommended surgery to remove the brain mass as part of their normal care
  • People whose doctor believes they have a life expectancy of more than 3 months
  • People with a Karnofsky performance score of 60 or above — this is a standard medical scale used by doctors to assess a person's general ability to carry out daily activities (confirm with trial site)
  • People who are willing to be told about the investigational nature of the study and are able to sign a written consent form before any study-specific procedures begin

Who may not be able to join:

  • People who, in their doctor's opinion, are unable to tolerate the imaging procedures involved in the study
  • People who are pregnant or breastfeeding at the time of screening — a urine pregnancy test will be carried out before the study injection for women who could potentially become pregnant
  • People who have a current medical condition, illness, or disorder that a doctor believes could put them at risk or affect their ability to safely take part in the study
  • People who have a medical reason that makes MRI scanning unsafe or unsuitable for them
  • People who are unable to understand the study information or cannot give informed consent on their own

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Ali Nabavizadeh, MD, University of Pensylvania

Phone: 8563643137

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
1 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Uptake Values (SUV)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov